Identification and Validation of Necroptosis-Related LncRNA Signature in Hepatocellular Carcinoma for Prognosis Estimation and Microenvironment Status

Abstract

Background: Hepatocellular carcinoma (HCC) is among malignancies with the highest fatality toll globally and minimal therapeutic options. Necroptosis is a programmed form of necrosis or inflammatory cell death, which can affect prognosis and microenvironmental status of HCC. Therefore, we aimed to explore the prognostic value of necroptosis-related lncRNAs (NRLs) in HCC and the role of the tumor microenvironment (TME) in immunotherapy.Methods: The RNA-sequencing data and clinical information were downloaded from The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC). NRLs were identified by Pearson correlation analysis. The signature was constructed using the LASSO–Cox regression analysis and evaluated using the receiver operating characteristic curve (ROC) and the area under the Kaplan–Meier curve. The nomogram was built based on clinical information and risk score. Gene set enrichment analysis (GSEA), immunoassay, half-maximum inhibitory concentration (IC50) analysis of the risk group, and the HCC subtype identification based on NRLs were also carried out. Finally, we detected the expression of lncRNAs in HCC tissues and cell lines in vitro.Results: A total of 508 NRLs were screened out, and seven NRLs were constructed as a risk stratification system to classify patients into distinct low- and high-risk groups. Patients in the high-risk group had a significantly lower overall survival (OS) than those in the low-risk group. Using multivariate Cox regression analysis, we found that the risk score was an independent predictor of OS. Functional analysis showed that the immune status of different patients was different. The IC50 analysis of chemotherapy demonstrated that patients in the high-risk group were more sensitive to commonly prescribed drugs. qRT-PCR showed that three high-risk lncRNAs were upregulated in drug-resistant cells, and the expression in HCC tissues was higher than that in adjacent tissues.Conclusion: The prediction signature developed in this study can be used to assess the prognosis and microenvironment of HCC patients, and serve as a new benchmark for HCC treatment selection.

NAD+ associated genes as potential biomarkers for predicting the prognosis of gastric cancer

“…Recently, lncRNAs have been identified as critical factors in cancer development [ 59 , 60 ]. In this study, firstly we found that the prediction model of NMRGs was not so good (AUC = 0.447).…”

Construction and Validation of a Novel Cuproptosis-associated lncRNA Signature as a Prognostic Biomarker in Hepatocellular Carcinoma

“…It is well established that lncRNAs take on an essential significance in the progression and development of various cancers including HCC [13,26,27]. Furthermore, previous studies have built and proven ferroptosis-associated, autophagy-associated, and necroptosis-associated lncRNA prognosis signatures for cancers [28][29][30].…”

Disulfidptosis-related lncRNAs are potential biomarkers for predicting prognoses in patients with hepatocellular carcinoma

“…LncRNA HEPFAL accelerates ferroptosis in HCC by regulating SLC7A11 ubiquitination [13] .The necroptosisrelated lncRNA signature in HCC for prognosis estimation and microenvironment status has been identi ed and validated [14] . Overexpression of the lncRNA HOTAIRM1 promotes lenvatinib resistance by downregulating miR-34a and activating autophagy in HCC [15] .…”